Race, Treatment, and Cardiovascular Health: A Study of Men with Prostrate Cancer
Abstract
As more men live with their prostate cancer, they face increased risk of cardiovascular disease (CVD); this risk is intensified by treatment type, in particular androgen deprivation therapy (ADT). There is a paucity of data exploring the risk of CVD among minority men with prostate cancer overall or by treatment type. We conducted a preliminary analysis examining pre and post diagnosis cholesterol profiles among men with prostate cancer, overall and by race and treatment type, using electronically available data on 2000 cases (1000 each African American and Caucasian). Pre-diagnosis, 1077 men (54%) had > or = 1 cholesterol level measured and post-diagnosis, 1489 men (74%) had > or = 1 cholesterol level measured. After adjusting for first measured cholesterol, there was evidence for a race by ADT interaction with change in cholesterol level (P=0.06). Compared to Caucasians never on ADT, both Caucasian and African-American men ever on ADT had an increase in cholesterol (1.6 + or = 1.5 mg/dL and 2.5 + or = 1.5 mg/dL, respectively), whereas African-American men never on ADT had a decrease in cholesterol (-1.33 mg/dL). ADT increased cholesterol levels in both African-American and Caucasian men with prostate cancer suggesting a need for guidelines for regular screening of men treated with ADT.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2010
- Accession Number
- ADA542124
Entities
People
- Andrea E. Cassidy-bushrow
Organizations
- Henry Ford Health